Orexo AB (publ) (ORX.ST)

SEK 20.8

(-5.24%)

Market Cap (In SEK)

716.55 Million

Revenue (In SEK)

638.8 Million

Net Income (In SEK)

-128.3 Million

Avg. Volume

20.36 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
9.18-24.0
PE
-
EPS
-
Beta Value
0.599
ISIN
SE0000736415
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Nikolaj Sorensen
Employee Count
-
Website
https://www.orexo.com
Ipo Date
2005-11-09
Details
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.